Your Location:Home >Products >intermediate >66985-17-9
pd_meltingpoint:231 °C
Purity:99%
Biochem/physiol Actions |
Ipratropium bromide monohydrate is a nonselective muscarinic acetylcholine receptor antagonist and a bronchodilator. In nebulized form, it is used for treating asthma and obstructive pulmonary diseases. It acts as a β2 adrenoreceptor agonist. Ipratropium bromide monohydrate is an anticholinergic agent and competes with acetylcholine. It promotes bronchodilation by stimulating sympathetic pathways. |
Drug interactions |
Potentially hazardous interactions with other drugs None known |
Metabolism |
After inhalation, around 10-30% of a dose is deposited in the lungs where it exerts its therapeutic effect. Only a small amount of ipratropium reaches the systemic circulation. The majority of a dose is swallowed but is poorly absorbed from the gastrointestinal tract. Ipratropium and its metabolites are eliminated in the urine and faeces. |
Definition |
ChEBI: The monohydrate form of ipratropium bromide. An anticholinergic drug, ipratropium bromide blocks the muscarinic cholinergic receptors in the smooth muscles of the bronchi in the lungs. This opens the bronchi, so providing relief in chronic obstructive pulm nary disease and acute asthma. |
InChI:InChI=1/C20H30NO3.BrH.H2O/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H;1H2/q+1;;/p-1
CAS:56-94-0
CAS:118685-33-9
CAS:2112737-90-1
CAS:717824-30-1